D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(86 sites)

China

Anhui Province Hospital, Hefei, Anhui

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing Municipality

Xuanwu Hospital Capital Medical University, Beijing, Beijing Municipality

Beijing Cancer Hospital, Beijing, Beijing Municipality

Peking University Third Hospital, Beijing, Beijing Municipality